Labcorp has recently secured FDA emergency use authorization for its VirSeq SARS-CoV-2 NGS test, bolstering its position in a competitive market. Despite reporting a revenue of $16 billion and facing a 15.4% decline in stock performance over the past year, the company has launched new testing programs, including at-home kits for diabetes screening. With quarterly earnings projected at $4.66 per share and a partnership with HealthVerity, Labcorp aims to enhance its drug development capabilities and navigate financial turbulence.
“Labcorp · is a · leading global life sciences company · true”
“Labcorp · reported revenue of · $16 billion · FY2021”
“Labcorp · signed · Tigerlily’s #InclusionPledge for Black Women · true”
“LabCorp · received · FDA’s EUA · VirSeq SARS-CoV-2 NGS test”
“LabCorp · announced · partnership · HealthVerity”
“LabCorp · gained · FDA’s EUA · for its VirSeq SARS-CoV-2 NGS Test”
“LabCorp · introduced · testing program · for advanced non-small cell lung cancer patients”
“LabCorp · launched · a test · for LAG-3 expression levels”
“LabCorp · announced · an at-home collection kit · for diabetes screening”
“Labcorp · announced · new collaboration with HealthVerity, Inc. · expand Labcorp’s comprehensive, end-to-end drug development and clinical trial programs”
“Labcorp · can align · de-identified patient data · with ten times greater accuracy than industry alternatives”
“Labcorp · is · an investor in HealthVerity · through the Labcorp Venture Fund”